Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Privia Health Group (PRVA)

Privia Health Q4 revenue rose 4.6% to $460.9 million; full-year GAAP EPS fell 42.1%

Mixed Impact 3 of 5 earnings Written later

Privia Health reported fourth-quarter 2024 revenue of $460.9 million, up 4.6%, and full-year revenue of $1.74 billion, up 4.7%. Full-year net income attributable to the company fell 37.7% to $14.4 million, while non-GAAP adjusted net income rose 19.8%, and the company gave 2025 guidance for GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million.

Key points

  • Q4 2024 net income attributable to Privia was $4.4 million, up from $2.8 million; diluted EPS was $0.03 versus $0.02
  • Full-year 2024 diluted EPS was $0.11 versus $0.19 in 2023, a 42.1% decline; non-GAAP adjusted diluted EPS rose 21.9% to $0.78
  • Full-year 2024 Adjusted EBITDA was $90.5 million, up 25.2%; year-end cash was $491.1 million with no debt
  • 2025 guidance: GAAP revenue of $1.8 billion to $1.9 billion and Adjusted EBITDA of $105 million to $110 million; guidance assumes no new business development activity

The filing

CompanyPrivia Health Group (PRVA)
Form8-K, current report
Filed with the SECFeb 27, 2025, 6:09 AM ET
Accession number0001759655-25-000016

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.